Nectar Lifesciences Faces CGST Writ Petition Challenge Over Tax Demand Reversal
Nectar Lifesciences Limited faces a civil writ petition filed by the Principal Commissioner of CGST Ludhiana challenging a favorable appellate order from May 27, 2025. The appellate order had dropped ₹89.32 crore in tax demands while confirming only ₹17.06 lakh liability. If the petition succeeds, the company could face significant financial exposure including the dropped demand plus interest and penalties. The company contests the petition with hearing scheduled for April 28, 2026.

*this image is generated using AI for illustrative purposes only.
Nectar Lifesciences Limited has informed stock exchanges about a material litigation development involving a civil writ petition filed by the Principal Commissioner of CGST Commissionerate, Ludhiana. The petition challenges a favorable appellate order that significantly reduced the company's tax liability.
Background of the Tax Matter
The development stems from an earlier appellate order dated May 27, 2025, issued by the Commissioner (Appeal). This order had provided substantial relief to Nectar Lifesciences by dropping a major portion of the tax demand while confirming only a minimal liability.
| Outcome of Appellate Order: | Details |
|---|---|
| Confirmed ITC Liability: | ₹17.06 lakh (CGST ₹8.53 lakh + SGST ₹8.53 lakh) |
| Penalty Imposed: | Equivalent to confirmed liability |
| Demand Dropped: | ₹89.32 crore along with interest and penalties |
| Remanded Amount: | ₹6.24 crore for fresh adjudication |
| Personal Penalties Quashed: | ₹25,000 each for three individuals |
CGST Authority's Challenge
The Principal Commissioner of CGST Commissionerate, Ludhiana has now filed a civil writ petition with the Hon'ble High Court of Punjab and Haryana, seeking to overturn the appellate decision. The petition requests the court to:
- Quash and set aside the appellate order dated May 27, 2025
- Restore the original order that was quashed by the appellate authority
- Grant interim stay on the operation of the appellate order
Potential Financial Impact
If the High Court allows the writ petition in full, Nectar Lifesciences could face significant financial exposure. The company has disclosed that it may be required to pay the ₹89.32 crore demand along with applicable interest and penalties, plus the ₹6.24 crore demand that was remanded.
| Risk Assessment: | Amount |
|---|---|
| Primary Exposure: | ₹89.32 crore plus interest and penalties |
| Additional Exposure: | ₹6.24 crore remanded demand |
| Current Status: | Final quantum not ascertainable |
Company's Response Strategy
Nectar Lifesciences has stated that it strongly contests the contentions raised in the writ petition and will file an appropriate response before the Hon'ble High Court. The company has also reserved its right to prefer an appeal before the Hon'ble Supreme Court if required, indicating its intention to pursue all available legal remedies.
Next Steps
The matter has been scheduled for hearing on April 28, 2026, before the Hon'ble High Court of Punjab and Haryana. The outcome of this hearing will determine whether the favorable appellate order remains intact or if the company faces renewed tax liability exposure.
Historical Stock Returns for Nectar Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.96% | -12.76% | -20.29% | -33.56% | -59.18% | -48.25% |
How might this prolonged tax litigation affect Nectar Lifesciences' cash flow and ability to invest in R&D or expansion plans over the next 12-18 months?
What impact could a potential ₹95+ crore tax liability have on the company's credit rating and borrowing costs if the High Court rules against them?
Will this litigation uncertainty influence institutional investors' confidence in Nectar Lifesciences' stock performance leading up to the April 2026 hearing?


































